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Purpose. Typical treatment of retroperitoneal sarcomas (RPSs) is surgery with or without radiation therapy for localized disease.
With surgery alone, local failure rates are as high as 90%; this led to radiation therapy playing an important role in the treatment
of RPSs. Methods. Thirty-one patients with retroperitoneal sarcoma treated with gross total resection and radiation therapy make
up this retrospective analysis. Nineteen were treated preoperatively and 12 postoperatively (median dose, 59.4Gy)—sixteen also
received intraoperative radiation therapy (IORT) (median dose, 11Gy). Patients were followed with stringent regimens, including
frequent CT scans of the chest, abdomen, and pelvis. Results. With a median follow-up of 19 months (range 1–66 months), the
2-year overall survival (OS) rate is 70% (median, 52 months). The 2-year locoregional control (LRC) rate is 77% (median, 61.6
months).The2-yeardistantdiseasefreesurvival(DDFS)rateis70%(mediannotreached).Therewerenodiﬀerencesinradiation-
related acute and late toxicities among patients treated pre- versus postoperatively, whether with or without IORT. Conclusions.
Compared to surgery alone, neoadjuvant or adjuvant radiation therapy oﬀers patients with RPS an excellent chance for long-term
LRC,DDS,andOS.TheintegrationofmoderntreatmentplanningforexternalbeamradiationtherapyandIORTallowsforhigher
doses to be delivered with acceptable toxicities.
Copyright © 2008 Timothy M. Zagar et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Retroperitoneal sarcomas (RPSs) make up a minority of soft
tissue sarcomas (STSs) diagnosed in the United States. In
2008, it is estimated that 10390 people will be diagnosed
withanSTS;ofthese,approximately20%,or2080,willoccur
in the retroperitoneum [1]. RPSs pose diﬃcult diagnostic
and therapeutic problems for physicians treating them.
As a result of their location, sarcomas that arise in this
area can grow to extremely large sizes (typically >10cm)
beforecausingsymptoms.Theirlargemassesmayencompass
critical anatomic structures, signiﬁcantly decreasing the rate
of complete surgical resectability [2–4]. Only approximately
half of RPSs are surgically resectable. Without adjuvant
therapy, the risk of local recurrence ranges from 68%
to more than 90% at 10 years [5–7]. The prospect of
adjuvant radiation therapy to “sterilize” positive surgical
margins and/or minimal gross residual disease has been
vital in the treatment of RPSs. Additionally, preoperative
radiation therapy is often used in an attempt to improve
resectability.
There has been no published randomized trial for pre-
operative versus postoperative radiation therapy in patients
with RPS, as there has been for soft tissue sarcomas of the
extremity [8], largely because of the paucity of cases. As
such, there is no consensus as to the sequencing, or even the2 Journal of Oncology
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Figure 1: (a) Locoregional control: all 31 patients. (b) Locoregional control: pre- versus postoperative EBRT (P = .79). EBRT = external
beam radiation therapy.
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Figure 2: (a) Distant disease free survival: all 31 patients. (b) Distant disease free survival: pre- versus postoperative EBRT (P = .73). EBRT
= external beam radiation therapy.Journal of Oncology 3
Table 1: Patient and tumor characteristics (all patients).
Parameter No. of patients (%)
Sex
Male 11 (35%)
Female 20 (65%)
Age (range) 56 (20–83)
Race
Caucasian 28 (90%)
African American 3 (10%)
History of tobacco use 11 (35%)
Family history of malignancy 7 (23%)
Breast cancer 4 (13%)
Breast and ovarian cancers 2( 6 % )
Sarcoma 1( 3 % )
Prior cancer 4 (13%)
Breast 1( 3 % )
Melanoma 1( 3 % )
Hodgkin’s disease 1( 3 % )
Prior radiation 3 (10%)
TNM stage
T2bN0M0 25 (81%)
T2bN0M1 4 (13%)
Desmoid 2( 6 % )
Grade
1 6 (19%)
2 6 (19%)
3 17 (55%)
AJCC stage
I 10 (32%)
III 15 (48%)
IV 4 (13%)
Recurrent RPS 7 (23%)
Pretreatment size of RPS (range) 10.5cm (4.0–20.0)
Histology
Leiomyosarcoma 15 (48%)
Liposarcoma 10 (32%)
Myxoid 3 (10%)
Dediﬀerentiated 4 (13%)
Desmoid 2( 6 % )
Malignant ﬁbrous histiocytoma 3 (10%)
Inﬂammatory myoﬁbroblastic sarcoma 1( 3 % )
CD 117 staining
Not done 16 (52%)
Negative 10 (32%)
Positive 5 (16%)
Imatinib mesylate given 1( 3 % )
Symptoms at presentation
Pain/discomfort 20 (65%)
Weight loss (range) 9 (31%) 10–30lbs
Early satiety/decreased appetite 6 (21%)
Nausea 3 (10%)4 Journal of Oncology
Table 1: Continued.
Parameter No. of patients (%)
Change in menses 2( 7 % )
Small bowel obstruction 2( 7 % )
need for radiation therapy for that matter. Radiation therapy
has been given in the preoperative setting [9–12], in the
hopes of converting a technically unresectable RPS to being
resectable. It has also been given in the preoperative [13]
and postoperative setting with concurrent chemotherapy
[14]. It can also be given in the postoperative setting to
help control any residual disease, be it gross or microscopic
[10, 11, 15–19]. Finally, radiation therapy can be given in
the intraoperative setting either with electrons from a linear
accelerator or with brachytherapy, both of which have been
shown to increase local control [9, 10, 12, 16, 18–20].
At our institution, preoperative radiation therapy with
or without intraoperative radiation therapy (IORT) has
been utilized for large, potentially diﬃcult-to-resect RPSs.
Radiation therapy is recommended in the postoperative
adjuvant setting in patients who had surgery prior to initial
referral, or for smaller RPSs that our surgeons feel they
can completely resect without having to sacriﬁce too much
normal anatomy for the sake of achieving a gross total resec-
tion (GTR). We report one of the largest single institution
cohorts of patients with RPS treated with modern radiation
therapy techniques, including a subset direct comparison
between those patients treated pre- versus postoperatively, to
elucidate any diﬀerences in both outcome and toxicities.
2.MaterialsandMethods
2.1. Patients. Between August 2000 and April 2008, 29
consecutive adult patients with a histologic diagnosis of
retroperitoneal sarcoma and 2 patients with recurrent/per-
sistent intraabdominal aggressive ﬁbromatosis (desmoid
tumor) were treated with at least one modality of radiation
therapy at Case Medical Center in University Hospitals. All
patients were presented to the biweekly multidisciplinary
sarcoma tumor board prior to treatment at our institution.
Data were collected retrospectively from paper charts and
electronic medical records after approval by our Cancer
Center Review Board and our Institutional Review Board.
2.2. Treatment Regimens
2.2.1. Pre- and Postoperative External Beam Radiotherapy.
Radiation therapy planning utilizing standard computed
tomography (CT)-guided 3-dimensional conformal tech-
niques was routinely performed, typically with 4 to 7 ﬁelds
used. As the techniques of intensity modulated (IMRT) and
image-guidedradiationtherapy(IGRT)utilizingTomoTher-
apy (Madison, Wis, USA) became available in 2004, they
were utilized as per the physician’s discretion. All radiation
treatment planning was performed by a senior radiation
oncologist (TJK).
2.2.2. Intraoperative Radiation Therapy (IORT). When clin-
ically indicated, IORT was administered via a Mobetron
linear accelerator with electron energies of 6 to 12MeV,
prescribed to the 90% isodose line (Intraop Medical, Inc.,
Sunnyvale, Calif, USA). After surgical resection of the RPS,
a ﬂat or beveled cylindrical cone (5–10cm) anchored by
a Bookwalter surgical clamp (Codman and Shurtleﬀ,I n c . ,
Raynham, Mass, USA) was placed by both the surgeon
and radiation oncologist over areas at high risk of residual
microscopic to minimal gross disease. No patients were
treated with IORT for unresectable disease. Dose-limiting
normal tissues that were in the desired IORT bed, if
mobile, were physically moved out of the ﬁeld—if they
were immobile, typically 3 half value layer lead wafers were
used for shielding. The technique of IORT and surgical
approaches to minimize acute and late IORT-related normal
tissue toxicities are previously detailed [21, 22].
2.2.3. Surgery. A gross total resection (GTR) was achieved
when the surgeon was able to resect all areas of visible
disease in the operating room—a subtotal resection (STR)
was performed when there was any amount of gross residual
disease left behind. An en bloc resection of the tumor mass
and expendible involved normal tissues was attempted in
all patients. Microscopic margin status was not routinely
reported, but was assumed to be positive along soft tissue,
bone, and vascular margins in the retroperitoneum.
2.2.4. Follow-Up. Patients were followed up by their treating
radiation oncologist after completing radiation every 3
months for the ﬁrst year, every 4 months for the 2nd year,
every 6 months for the 3rd and 4th years, then annually, with
a contrast enhanced CT of the chest, abdomen, and pelvis,
and full labs with each visit. Other ancillary studies were
performed as clinically indicated.
2.2.5.NormalTissueToxicityAnalyses. Acute(1–90daysafter
radiation therapy commencement) and chronic (>90 days)
toxicities were graded according to the Radiation Therapy
Oncology Group (RTOG) acute and late radiation morbidity
scoring criteria [23].
2.2.6. Deﬁnition of Treatment Outcomes and Statistical
Considerations. The primary endpoints of this study were
locoregional control (LRC), distant disease-free survival
(DDFS), and overall survival (OS). A locoregional failure
was deﬁned as any tumor recurrence within the abdomi-
nal/retroperitonealcavity,includingwithinradiationportals.
Distant metastases (typically to liver and/or lung) were
determined by CT examinations with or without subsequent
histopathologic conﬁrmation. OS, DDFS, and LRC wereJournal of Oncology 5
Table 2: Patient, tumor, and treatment characteristics.
Parameters Preoperative EBRT group (n = 19) Postoperative EBRT group (n = 12) P value
Gender
Female 12 (63%) 8 (67%) 1.00
Male 7 (37%) 4 (33%)
Age at presentation
≤50 years 8 (42%) 2 (17%) .24
>50 years 11 (58%) 10 (83%)
AJCC stage
I 5 (26%) 5 (42%)
.24 III 12 (63%) 3 (25%)
IV 2 (11%) 2 (17%)
Grade
1 3 (16%) 3 (25%)
.66 2 4 (21%) 2 (17%)
3 12 (63%) 5 (42%)
Tumor size
≤10cm 7 (37%) 9 (75%) .07
>10cm 12 (63%) 3 (25%)
Lesion presentation
Primary 17 (89%) 7 (58%) .08
Recurrent 2 (11%) 5 (42%)
Histology
Leiomyosarcoma 9 (47%) 6 (50%)
.72 Liposarcoma 7 (37%) 3 (25%)
Other 3 (16%) 3 (25%)
Extent resection
STR 4 (21%) 1 (8%) .62
GTR 15 (79%) 11 (92%)
Organs removed
No 9 (47%) 3 (25%) .27
Yes 10 (53%) 9 (75%)
Chemo
No 16 (84%) 9 (75%) .65
Yes 3 (16%) 3 (25%)
IORT
No 6 (32%) 9 (75%) .03
Yes (1pt each arm had 2 ﬁelds) 13 (68%) 3 (25%)
Radiotherapy dose
EBRT median (range) 59.4Gy (36.8–63.4Gy) 59.4Gy (54–68.4) .79
IORT median (range) 11Gy (10–12Gy) 11Gy (10–12Gy)
IMRT
No 17 (89%) 4 (33%) .002
Yes 2 (11%) 8 (67%)
Time to complete EBRT Median (range) 45 days (17–90 days) 44 days (41–55 days) .76
Length of F/U Median (range) 22 months (0.6–56.5 months) 13.05 months (1.4–66.4 months) .55
EBRT = external beam radiation therapy; STR = subtotal resection; GTR = gross total resection; IORT = intraoperative radiation therapy; IMRT = intensity
modulated radiation therapy; F/U = follow-up.6 Journal of Oncology
Table 3: Cox regression multivariate analysis when controlled for pre- versus postoperative treatment.
Locoregional control Distant disease free survival Overall survival
Age P = .98 P = .79 P = .81
Gender P = .76 P = .12 P = .72
Stage P = .95 P = .21 P = .99
Grade P = .81 P = .57 P = .93
Tumor size P = .76 P = .46 P = .96
Primary versus recurrent P = .60 P = .27 P = .65
Histology P = .70 P = .53 P = .92
GTR/STR P = .55 P = .41 P = .77
IORT P = .55 P = .42 P = .76
Chemo P = .83 P = .39 P = .77
EBRT dose P = .79 P = .28 P = .60
Organ resected P = .85 P = .34 P = .66
GTR = gross total resection; STR = subtotal resection; IORT = intraoperative radiation therapy; EBRT = external beam radiation therapy.
calculated from the ﬁrst day of radiation therapy administra-
tion. The patients were censored at either their last follow-
up, if they remained alive and/or disease free, or the date
of their local or distant failure or death. The Kaplan-Meier
method was used to compute LRC, DDFS, and OS [24].
Cox models were used for multivariate analysis of prognostic
factors [25]. Chi square and Fisher’s exact tests were utilized
for categorical variables and median tests were utilized to
analyze the continuous variables to compare patient groups
treated pre- versus postoperatively [26]. All measures tests
were analyzed with statistical software (SPSS 12.0, SPSS, Inc,
Chicago,Ill,USA),witha2-sidedalphalevelof0.05regarded
as statistically signiﬁcant.
3. Results
3.1. Patient and Treatment Characteristics. Twenty-nine con-
secutive patients with biopsy proven retroperitoneal sarcoma
and 2 patients with intraabdominal ﬁbromatosis (desmoid
tumor) were treated and closely followed over this 8+ year
period, for a median of 19 months (range 1–66 months).
The 2 patients with large intraabdominal desmoid tumors
were included in this analysis due to the highly aggressive
nature of their lesions—in fact, one patient had positive
lymph nodes at the time of surgical resection. Females
made up the majority (65%) of patients, and Caucasians
accounted for the overwhelming majority (90%). Most
frequently, patients presented with either pain or some type
of vague abdominal discomfort, or unintentional weight
loss (Table 1). Overall, 26 (84%) patients were able to
have a gross total resection of their RPSs; 15 (79%) of
the patients were treated preoperatively and 11 (92%) of
the patients were treated postoperatively. Patients treated
postoperatively generally had smaller tumors (≤10cm) at
presentation. When separated into sequencing of treatment,
19 (61%) patients were treated preoperatively (median dose
59.4Gy, range 36.8–63.4Gy), with the goal of improving the
likelihood of achieving gross total resection; one patient was
palliated for her SVC syndrome, which was her presenting
symptom. Twelve (39%) patients were treated in the postop-
erative setting (median 59.4Gy, range 54–68.4Gy) (Table 2).
Both groups were well matched with respect to patient
characteristics,pathology,grade,clinicalstage,histology,and
extent of surgical resection. However, the only statistically
signiﬁcant diﬀerence between the groups was the use of
IORT and IMRT. Thirteen (68%) patients were treated with
preoperativeEBRTreceivedIORT,comparedtoonly3(25%)
patients who received IORT followed by postoperative EBRT,
based on the recommendations of the multidisciplinary
sarcoma tumor board (P = .03, Table 2). Eight (67%)
patients treated with postoperative EBRT were treated with
IMRT/IGRT versus only 2 (11%) patients in the preoperative
group, based on the availability of TomoTherapy (P = .003).
3.1.1. Locoregional Control. Overall, the 31 patients have a
medianlocoregionalcontrolrate(LRC)of61.6months,with
a 2-year LRC rate of 77% (SE +/ − 18%) (Figure 1(a)).
Two patients in the preoperative group and 1 patient in
the postoperative group developed a locoregional failure as
their ﬁrst site of failure. There was no statistically signiﬁcant
diﬀerence in LRC rates in patients treated pre- versus
postoperatively (P = .79) (Figure 1(b)). The use of IORT did
n o th a v ea ni m p a c to nL R C( P = .550) (Table 3).
3.1.2. Distant Metastases. The median distant disease-free
survival (DDFS) has not yet been achieved, with a 2-year
DDFS of 70% (SE +/− 18%) (Figure 2(a)). All 7 patients
who developed metastatic disease did so within the ﬁrst
14 months of beginning radiation therapy (median 4.8
months, range 4.2–14.2 months). Treatment for metastases
was physician dependent—all were oﬀered chemotherapy.
One patient underwent multiple video-assisted thorascopic
(VATS) resections of his pulmonary metastases, while one
other received palliative radiation therapy to her lung
metastases. Four patients in the preoperative group and
2 patients in the postoperative group developed distant
metastases as their ﬁrst site of failure—two patients in
the postoperative group developed synchronous distant andJournal of Oncology 7
Table 4: RTOG acute and late toxicities of radiation.
Parameters Preoperative EBRT group (n = 19) Postoperative EBRT group (n = 12) P value
Acute (≤90 days)
GI
Grade 1-2 16 (84%) 11 (92%) .70
Grade 3-4 1 (5%) 0 (0%)
GU
Grade 1-2 0 (0%) 3 (25%) .05
Grade 3-4 0 (0%) 0 (0%)
Wound complications
Grade 1-2 0 (0%) 1 (8%) .39
Grade 3-4 0 (0%) 0 (0%)
Infection
Grade 1-2 0 (0%) 0 (0%) 1.00
Grade 3-4 1 (5%) 0 (0%)
Skin
Grade 1-2 2 (11%) 1 (8%) 1.00
Grade 3-4 0 (0%) 0 (0%)
Pain
Grade 1-2 11 (58%) 5 (42%) .47
Grade 3-4 0 (0%) 0 (0%)
Neurologic
Grade 1-2 2 (11%) 0 (0%) .51
Grade 3-4 0 (0%) 0 (0%)
Gynecologic
Grade 1-2 0 (0%) 0 (0%) 1.00
Grade 3-4 1 (5%) 0 (0%)
Late (>90 days)
GI
Grade 1-2 1 (5%) 2 (17%) .51
Grade 3-4 3 (16%) 3 (25%)
GU
Grade 1-2 0 (0%) 0 (0%) 1.00
Grade 3-4 1 (5%) 0 (0%)
Wound complications
Grade 1-2 0 (0%) 0 (0%) 1.00
Grade 3-4 1 (5%) 0 (0%)
Infection
Grade 1-2 0 (0%) 0 (0%) .31
Grade 3-4 4 (21%) 2 (17%)
Skin
Grade 1-2 0 (0%) 0 (0%) NS
Grade 3-4 0 (0%) 0 (0%)
Pain
Grade 1-2 1 (5%) 0 (0%) 1.00
Grade 3-4 0 (0%) 0 (0%)
Neurologic
Grade 1-2 1 (5%) 0 (0%) 1.00
Grade 3-4 0 (0%) 0 (0%)
Gynecologic
Grade 1-2 0 (0%) 0 (0%) 1.00
Grade 3-4 2 (11%) 1 (8%)8 Journal of Oncology
Table 4: Continued.
Parameters Preoperative EBRT group (n = 19) Postoperative EBRT group (n = 12) P value
Lymphedema
Grade 1-2 1 (5%) 0 (0%) 1.00
Grade 3-4 0 (0%) 0 (0%)
RTOG = Radiation therapy oncology group; EBRT = external beam radiation therapy; GI = gastrointestinal; GU = genitourinary.
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Figure 3:(a)Overallsurvival:all31patients.(b)Overallsurvival:pre-versuspostoperativeEBRT(P = .14).EBRT=externalbeamradiation
therapy.
locoregional failures. There was no statistically signiﬁcant
diﬀerence in DDFS rates in patients treated pre- versus
postoperatively (P = .73), whether with or without IORT
(P = .42); see Figure 2(b) and Table 3.
3.2. Overall Survival. The median overall survival for this
patient cohort was 52 months, with a 2-year OS rate of
70% (SE + / − 19%) (Figure 3(a)). Nine patients died
during follow-up, with 8 of these directly attributable to
retroperitoneal sarcoma. The other death occurred in a
patient who suﬀered from a complicated postoperative
course, including intractable clostridium diﬃcile colitis. At
last follow-up (5.8 months), she was free of both local and
recurrent disease, but she was ultimately lost to follow-up.
Therewasno statisticallysigniﬁcant diﬀerencein DDFS rates
in patients treated pre- versus postoperatively (P = .14),
whether with or without IORT (P = .77); see Figure 3(b)
and Table 3.
3.3. Prognostic Factors for LRC, DDFS, and OS. There were
two trends that approached statistical signiﬁcance; those
patients treated postoperatively had a trend to have lesions
≤10cm (P = .07), and were more likely to present with
recurrent disease (P = .08). In our cohort of patients,
after controlling for whether patients were treated in the
preoperative or postoperative setting, none of the commonly
cited characteristics had a statistically signiﬁcant impact on
LRC, DDFS, or OS, on multivariate analysis (Table 3).
3.3.1. Toxicity. Most patients (90%) completed the planned
course of radiation therapy without signiﬁcant (≥grade 3)
acute eﬀects. Acute and late toxicities were similar between
the pre- and postoperative groups (Table 4). There were 3
grade 3-4 acute radiation-related toxicities (all 3 in the pre-
operative group), and 17 grade 3-4 late toxicities (11 in the
preoperative group, 6 in the postoperative group)—no grade
5 treatment-related toxicities occurred. The most common
acute side eﬀect seen, with almost 90% of patients overall
experiencing, was grade 1-2 gastrointestinal complaints,
most commonly being nausea and/or diarrhea. These grade
1-2 toxicities responded to conservative medical treatment.
Late toxicities occurred less frequently and there were no
statistically signiﬁcant diﬀerences in late grade 3-4 toxicities
between those patients treated pre- versus postoperativelyJournal of Oncology 9
(Table 4). Once again, late GI toxicities were the most
common type of a late side eﬀect—when they occurred, they
were more often grade 3 to 4, including requiring emergency
surgery for small bowel obstruction related to adhesions
(one patient each in the preoperative and postoperative
groups). There was one grade 1 (asymptomatic) jejunal
stricture found at surgery for another reason, in a patient
treated postoperatively, that was presumed to be radiation-
related. One patient who was treated with postoperative
radiation therapy for his second locoregional failure, and
thenpreoperativelyforhisthirdlocoregionalfailure,suﬀered
from chronic small bowel obstructions. The only ﬁstula that
was documented in our series occurred in a patient who had
5 metachronous locoregional failures, and who was radiated
preoperatively with gross total resection of her fourth and
later ﬁfth locoregional failures.
A total of 16 patients reported grade 1-2 pain or
abdominal discomfort during radiation therapy—11 in the
preoperative group and 5 in the postoperative group (P =
.47). As these tumors are often symptomatic with pain at
presentation, a multifactorial cause of the pain/discomfort
was likely. Narcotics were used judiciously in these patients.
Those patients treated postoperatively had more frequent
acute grade 1-2 genitourinary-related toxicities, when com-
pared to the preoperative cohort (P = .05). There was no
statistically signiﬁcant diﬀerence in wound healing and/or
infection in the two diﬀerent cohorts—3 patients in the
preoperative group and 1 patient treated postoperatively
developed abscesses more than 90 days after radiation that
required drainage (P = .31). Radiation-induced menopause
was seen in 3 patients—2 treated preoperatively, and one in
the postoperative setting.
4. Discussion
Feng et al. reported on a large group of 85 patients with
RPS radiated over a 20-year period [11]. Their 2-year LC,
DDFS, and OS rates were 66%, 62%, and 70%, compared to
our 77%, 70%, and 70%, respectively. They were the ﬁrst to
report an apparent dose response relationship with adjuvant
radiation therapy for RPS, with higher doses (≥55.8Gy)
being associated with improved LC, but with no eﬀect on
overall survival [11].Typically,dosesof45Gyto50.4Gyhave
been utilized in the preoperative setting for RPSs [9, 10, 12,
13]. Our 2-year rate of LRC may be, in fact, due to the higher
doses of radiation used (median dose, 59.4Gy) which may
have an impact on DDFS. We routinely used this higher dose
in the preoperative setting, as we have extrapolated from our
owninstitution’sdataforextremitysofttissuesarcomas,with
all patients—both those treated pre- and postoperatively—
receiving a median dose of 59.4Gy [27].
A direct comparison of treatment outcomes following
combined surgery and radiation therapy for patients with
retroperitoneal sarcomas is particularly diﬃcult as there
is no standardized deﬁnition of what is a local failure.
Some reports, like our study, deﬁne a local failure as any
recurrence of disease in the abdominal cavity, save the
hepatic parenchyma [9]. Other reports use more stringent
deﬁnitions and divide locoregional failure into “central”
(within the IORT ﬁeld), “local” (if within the EBRT ﬁeld),
“regional” (if in regional lymphatics), “peritoneal” (if seed-
ing occurred), and “distant” (if beyond the regional site)
[10]. In our series, we had no central or local failures. The
predominant mode of failure was regional, but not within
lymph nodes.
Our series reports a high rate of gross total resections.
Twenty-six(84%)patients—ﬁfteentreatedwithpreoperative
radiation, and 11 treated postoperatively—were able to
undergo a GTR. On presentation, 2 patients were deemed by
our surgeons to have technically unresectable tumors. Both
were treated with preoperative radiation—one subsequently
had his tumor respond enough to undergo a GTR. Both
patients with technically unresectable disease eventually
developed pulmonary metastases. The patient who had a
GTR also had 2 separate metastectomies of lung metastases
and remained without evidence of further recurrent disease
29 months after initial treatment.
We advocate a stringent follow-up regimen for these
patients. The National Comprehensive Cancer Network
(NCCN)guidelinesrecommendfollowingpatientsevery3to
6 months for the ﬁrst 2 to 3 years with CTs of the abdomen
and pelvis (with consideration of chest imaging) [28]. We
routinely recommend CTs also of the chest every 3 and 4
months for the ﬁrst 2 years, as we have seen that all patients
who develop metastatic disease do so within the ﬁrst 15
months of therapy. This regimen allows for identiﬁcation of
patients who might be candidates for initial metastectomy
for oligometastases or systemic therapy at an earlier time for
multiple pulmonary lesions. While there may be an element
of lead-time bias with this imaging regimen, we believe
that, with early identiﬁcation of metastases, we can prolong
disease-free intervals, while the distant disease burden is still
manageable.
Many patients with RPS ultimately fail distantly and
systemic therapies have not proven to be eﬃcacious. One
potential future direction in the treatment of RPSs mirrors
the targeted therapy revolution currently occurring with var-
iousmalignancies.Fifteenof31patients’tumorswerestained
for the presence of CD-117 (c kit) and of the 5 patients
tumors that demonstrated varying degrees of positivity by
immunohistochemistry, one patient received 4 months of
imatinib mesylate in the preoperative setting during her
radiation therapy. However, repeat immunohistochemistry
for CD-117 was negative on the resected residual mass and
no post-operative imatinib mesylate was given. This patient
remains clinically and radiographically disease-free at 40
months.
As our results demonstrate, if a patient is to develop
metastatic disease, he is at highest risk within the ﬁrst years
and a half after treatment. Chemotherapy might have a role
in the early setting, and not just be reserved for patients
who have already developed metastatic disease. Pisters et al.
evaluated the use of doxorubicin concurrent with radiation
therapy, and found that one could escalate to a dose of
50.4Gy safely [13]. However, Glenn et al. from the National
Cancer Institute reported increased acute toxicities with
the use of postoperative triple chemotherapy (including10 Journal of Oncology
doxorubicin) during radiotherapy in patients with resectable
RPSs, without an overall survival beneﬁt [14].
Overall, the acute toxicities associated with the modern
day use of pre- or postoperative radiation therapy were
mild. Thirty of 31 patients completed radiation therapy as
prescribed. The patient who did not complete radiation
therapy had initially presented with metastatic disease and
small bowel obstruction secondary to his large tumor. He
ultimately had palliative bypass surgery and succumbed
to his distant disease. There were three grade 3-4 acute
radiation-related toxicities (all 3 in the preoperative group),
and six grade 3-4 late GI toxicities (3 in the preoperative
group, 3 in the postoperative group), with the formation of
only one treatment related bowel ﬁstula. For comparison,
Peterson et al. reported 12 cases of grade 3 or higher
GI complications in her series of 87 (43 with primary
disease, and 44 with recurrent disease) patients with RPS;
7 of these patients had ﬁstula formation [10]. In our
series, 6 patients (4 in the preoperative group, 2 in the
postoperative group) also experienced late grade 3-4 infec-
tious complications, requiring drainage of retroperitoneal
abscesses and prolonged intravenous antibiotics. Grading
radiation-related toxicities in patients with RPS is espe-
cially diﬃcult, and even more so in patients who present
with extremely large and/or recurrent tumors. Often times
multiple abdominal surgeries have been performed—a fact
alone that dramatically raises the incidence of late toxicities.
There is some toxicity that must be assumed when treating
these large tumors—without radiation, the risk of local
recurrenceisunacceptablyhigh,andthelikelihoodofsimilar
toxicities secondary to tumor growth alone is similarly
high.
The use of IORT has been shown to increase local
control, without adding signiﬁcantly to acute and late
toxicities from surgery [9, 10, 12, 16, 18, 19]. However,
peripheral neuropathy has been documented with the clin-
ical and experimental use of IORT to doses of ≥20Gy [29,
30]. Importantly, the incidence of IORT-related peripheral
neuropathy is not increased with the use of external beam
radiation therapy [29, 30]. In our cohort of patients, only
one patient experienced a late grade 2 neuropathy. This
patient received preoperative radiation and IORT for her
fourth and ﬁfth locoregional failures. IORT doses of 10 to
12Gy as utilized in our study almost uniformly preclude the
development of late neurologic sequelae. However, IORT did
not appear to signiﬁcantly impact LRC, DDFS, or OS in our
patients.
The American College of Surgeons Oncology Group
attempted a phase III trial, which randomized patients with
resectable RPS to surgery alone versus preoperative radiation
therapy followed by surgical resection [31]. However, even
with excellent planning and organization, the study was
closed because of slow accrual. Thus, a deﬁnitive answer
from a prospective randomized trial regarding the eﬃcacy of
preoperative radiation will not be available in the foreseeable
future. Future studies/trials may need to include randomiza-
tion of patients to surgery alone, preoperative radiation with
surgery, and surgery with postoperative radiation therapy.
Adding chemotherapy in the neo- or adjuvant setting, so as
to reduce the risk of developing metastatic disease, can also
be considered.
In summary, high dose (59.4Gy) preoperative or post-
operative radiation therapy is safe and eﬃcacious in the
treatment of RPSs. Based upon our experience, we recom-
mend the consideration of either neoadjuvant or adjuvant
radiation in patients with retroperitoneal sarcoma, as well
as the possibility of IORT if there is a high likelihood of
residual microscopic or minimal gross disease at the time
of surgical resection. We also recommend routine use of
follow-up chest CT scans along with abdominal and pelvic
CT scans. Some patients who initially present with locally
r e c u r r e n td i s e a s ea r ea b l et oh a v el o n g - t e r md i s e a s ef r e e
intervals when treated with radiation therapy at the time of
initial recurrence. However, as patients who receive radiation
more than one time for their RPS recurrences, the severity of
adverse related events increases. Further research needs to be
done, including the development of better systemic agents to
combat these diﬃcult-to-treat tumors.
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